Log In
BCIQ
Print this Print this
 

Biosimilar adalimumab (DA-3113, DMB-3113)

  Manage Alerts
Collapse Summary General Information
Company Dong-A Socio Holdings Co. Ltd.
DescriptionBiosimilar of adalimumab, a human mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionTumor necrosis factor (TNF) alpha inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerMeiji Seika Pharma Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today